Congressman Abe Hamadeh has recently addressed concerns regarding the availability of thyroid medications, as reflected in a series of posts from his official office account. The posts highlight both his engagement with the Food and Drug Administration (FDA) and ongoing communication with constituents.
On August 18, 2025, the Office of Congressman Abe Hamadeh posted: “NEW
Congressman Abe Hamadeh Questions FDA About Availability of Popular Thyroid Medications
Read Press Release
https://t.co/51t4D0JMQN“.
The following day, on August 19, 2025, another post stated: “Congressman Hamadeh has heard from people across his district who believe their health will be negatively affected by the elimination of these thyroid medications
He is confident that Dr. Makary & his team will give serious consideration to these concerns https://t.co/Ilg3GnhGJv“.
Later that same day, a third post read: “NEW
Congressman Hamadeh loves to read letters from his constituents, and our office is always ready to help you with casework.
Contact us here
https://t.co/zazKeXweAWhttps://t.co/4JmIpnBX24“.
Abraham Hamadeh was elected to Congress in 2024 after defeating Gregory Whitten in the general election by securing 56.5% of the vote compared to Whitten’s 43.5%. These recent communications indicate that Congressman Hamadeh continues to focus on constituent outreach and healthcare issues since taking office.
